Oncocyte to Announce Second Quarter 2022 Financial Results
July 27 2022 - 4:01PM
Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics
company with the mission to improve patient outcomes by providing
personalized insights that inform critical decisions throughout the
patient care journey, announced today that it will release its
second quarter 2022 financial results on Wednesday, August 10,
2022. In conjunction with the release, Oncocyte will host a
conference call and webcast that day at 1:30 p.m. Pacific Time /
4:30 p.m. Eastern Time to discuss its financial results and recent
highlights.
Interested parties may access the live call via
telephone by dialing (877) 407-9716 for domestic callers or (201)
493-6779 for international callers, using conference ID: 13731553.
The live webinar of the call may be accessed by visiting the
“Events & Presentation” section of the Company’s website at
https://investors.oncocyte.com. A replay of the webinar will be
available on the Company’s website shortly after the conclusion of
the call.
About OncocyteOncocyte is a precision
diagnostics company with a mission to improve patient outcomes by
providing personalized insights that inform critical decisions
throughout the patient care journey.
Through its proprietary tests and pharmaceutical services
business, the Company aims to help save lives by accelerating the
diagnosis of cancer and advancing cancer care. The Company’s tests
are designed to help provide clarity and confidence to physicians
and their patients at every stage. DetermaRx™ identifies
early-stage lung cancer patients who are at high risk for cancer
recurrence and who may benefit from adjuvant chemotherapy.
DetermaIO™ is a gene expression test that assesses the tumor
microenvironment to predict response to immunotherapies. The
Company’s pipeline of tests in development also includes
DetermaTx™, which will assess mutational status of a tumor,
DetermaCNI™, a blood-based monitoring test, DetermaMx™, a long-term
recurrence monitoring test, and VitaGraft™, a blood-based solid
organ transplantation monitoring test. In addition, Oncocyte’s
pharmaceutical services provide companies that are developing new
cancer treatments a full suite of molecular testing services to
support the drug development process.
DetermaRx™, DetermaIO™, DetermaTx™, DetermaCNI™, DetermaMx™ and
VitaGraft™ are trademarks of Oncocyte Corporation.
Investor ContactCaroline CornerICR
Westwicke(415) 202-5678caroline.corner@westwicke.com
Media ContactMegan KernanICR Westwicke
Healthcare PRTel: 646.677.1870Megan.kernan@westwicke.com
Oncocyte (NASDAQ:OCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncocyte (NASDAQ:OCX)
Historical Stock Chart
From Apr 2023 to Apr 2024